L. Wyrwicz, J. Taieb, T. Price, J. Bachet, M. Karthaus, L. Vidot, Bénédicte Chevallier, T. Reisländer, L. Weiss, V. Heinemann
{"title":"三氟吡啶/替吡拉西的临床和生活质量结果：PRECONNECT和TALLISUR研究","authors":"L. Wyrwicz, J. Taieb, T. Price, J. Bachet, M. Karthaus, L. Vidot, Bénédicte Chevallier, T. Reisländer, L. Weiss, V. Heinemann","doi":"10.2217/crc-2022-0013","DOIUrl":null,"url":null,"abstract":"Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT and TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS and QLQ-C30 GHS in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 patients were included. There was no clinically relevant change from baseline in QLQ-C30 GHS score through cycle 7. 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration. The association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time was significant (HR 1.71 [95% CI: 1.4, 2.2]). Conclusion: ECOG PS and QLQ-C30 GHS scores were maintained during FTD/TPI treatment, and these measures were associated. Factors that increased the risk of deterioration included the presence of liver/lung metastasis, younger age and shorter time since first metastasis. Clinical Trial Registration: PRECONNECT (EudraCT Number: 2016-002311-18 ) and TALLISUR (EudraCT-Number: 2017-000292-83 ).","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies\",\"authors\":\"L. Wyrwicz, J. Taieb, T. Price, J. Bachet, M. Karthaus, L. Vidot, Bénédicte Chevallier, T. Reisländer, L. Weiss, V. Heinemann\",\"doi\":\"10.2217/crc-2022-0013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT and TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS and QLQ-C30 GHS in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 patients were included. There was no clinically relevant change from baseline in QLQ-C30 GHS score through cycle 7. 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration. The association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time was significant (HR 1.71 [95% CI: 1.4, 2.2]). Conclusion: ECOG PS and QLQ-C30 GHS scores were maintained during FTD/TPI treatment, and these measures were associated. Factors that increased the risk of deterioration included the presence of liver/lung metastasis, younger age and shorter time since first metastasis. Clinical Trial Registration: PRECONNECT (EudraCT Number: 2016-002311-18 ) and TALLISUR (EudraCT-Number: 2017-000292-83 ).\",\"PeriodicalId\":43638,\"journal\":{\"name\":\"Colorectal Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-08-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Colorectal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/crc-2022-0013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/crc-2022-0013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies
Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT and TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS and QLQ-C30 GHS in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 patients were included. There was no clinically relevant change from baseline in QLQ-C30 GHS score through cycle 7. 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration. The association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time was significant (HR 1.71 [95% CI: 1.4, 2.2]). Conclusion: ECOG PS and QLQ-C30 GHS scores were maintained during FTD/TPI treatment, and these measures were associated. Factors that increased the risk of deterioration included the presence of liver/lung metastasis, younger age and shorter time since first metastasis. Clinical Trial Registration: PRECONNECT (EudraCT Number: 2016-002311-18 ) and TALLISUR (EudraCT-Number: 2017-000292-83 ).
期刊介绍：
Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
